Profilo
Rebecca Cohen is currently working as an Investor Relations Contact at Ikena Oncology, Inc. Previously, she worked as the Head-Corporate & Investor Relations at SQZ Biotechnologies Co. from 2017 to 2018.
She also served as an IR & Corporate Communications Contact at Epizyme, Inc.
Posizioni attive di Rebecca Cohen
Società | Posizione | Inizio |
---|---|---|
IKENA ONCOLOGY, INC. | Investor Relations Contact | - |
Precedenti posizioni note di Rebecca Cohen
Società | Posizione | Fine |
---|---|---|
SQZ BIOTECHNOLOGIES COMPANY | Investor Relations Contact | 01/07/2018 |
EPIZYME, INC. | Public Communications Contact | 01/05/2016 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
IKENA ONCOLOGY, INC. | Health Technology |
Aziende private | 1 |
---|---|
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Rebecca Cohen